# Genome & Company

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genome-company

- Industry: Biotechnology
- Headquarters: Suwon-si, South Korea
- Website: www.genomecom.co.kr
- Total disclosed funding: $14M
- Latest round: Series B (Apr 5, 2018)
- Investors on record: 6

## About

Founded in 2015 and based in Suwon, South Korea, Genome & Company develops pharmaceutical treatments for cancer and obesity using microbiome-based drugs. In March 2026, Susung Asset Management, Csquared Global Asset Management, Brain Asset Management, NH Hedge Asset Management, DongKoo Bio&Pharma, A ONE Asset Management, Welcome Asset Management, and Dyne Asset Management acquired 467,287 shares in Genome & Company at KRW 6,420 apiece for KRW 2.99 billion, in a PIPE transaction. The company will allocate the March 2026 funds toward technology transfer for its preclinical stage pipeline.

## Funding rounds

- Series B, Apr 5, 2018, $10M — Korea Investment Partners, DSC Investment, Premier Partners, Korea Omega Investment Corp., Paratus Investment, Macrogen
- Series A, Dec 22, 2016, $3.4M — Korea Investment Partners, DSC Investment, Paratus Investment

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A, Series B
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A, Series B
- Paratus Investment (https://capitalatlas.ai/funds/paratus-investment) — Series A, Series B
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series B
- Korea Omega Investment Corp. (https://capitalatlas.ai/funds/korea-omega-investment-corp) — Series B
- Macrogen — Series B